The series, under normal circumstances, invests at least 95% of its net assets in American Depositary Receipts ("ADRs") of the Novo Nordisk A/S (B Shares) (the "Company"). The series will not invest directly in the company. The fund is non-diversified.
Company profile updated October 15, 2026.
As of October 12, 2026. Daily closing data may differ from the live quote shown in the dashboard.
Compare the company’s price history and fundamentals in the dashboard. Explore disclosed trading and ownership activity in these research collections: